Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

doi:10.4251/wjgo.v15.i1.143

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1711)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

970

Figures (1-3)

143

Tables (1-6)

118

Sum=1353

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

127

Download

231

Sum=358

Jan 15, 2023 (publication date) through May 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2023; 15(1): 143-154
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143

Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

Jun-Ping Wang, Jian-Lei Du, Ya-Ying Li

Jun-Ping Wang, Jian-Lei Du, Ya-Ying Li, Pharmacy Department, Zhumadian Central Hospital, Zhumadian 463000, Henan Province, China

Author contributions: Wang JP design the experiment; Wang JP, Du JL and Li YY drafted the work; Du JL and Li YY collected the data; Wang JP and Du JL analysed and interpreted data; Wang JP, Du JL and Li YY revised and proofed the manuscript.

Institutional review board statement: The study was reviewed and approved by the Zhumadian Central Hospital Institutional Review Board (Approval No. 2022083).

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: There is no conflict of interest.

Data sharing statement: All data and materials are available from the corresponding author.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jun-Ping Wang, BSc, Pharmacist, Pharmacy Department, Zhumadian Central Hospital, No. 747 West Section of Zhonghua Road, Zhumadian 463000, Henan Province, China. wangjp2023@163.com

Received: November 14, 2022
Peer-review started: November 14, 2022
First decision: November 30, 2022
Revised: December 6, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 15, 2023

ARTICLE HIGHLIGHTS

Research background

Surgery, radiotherapy, and chemotherapy are often used for the treatment of advanced gastric cancer. Although chemotherapy is one of the main treatment options, there is no unified or standardized treatment; therefore, the identification of effective treatment options for patients with advanced gastric cancer is particularly important.

Research motivation

The conventional chemotherapy regimen for advanced gastric cancer consists of oxaliplatin combined with fluorouracil. However, studies have shown that treatment with only oxaliplatin combined with fluorouracil is not very effective in advanced gastric cancer.

Research objectives

This study is designed to investigate the short-term efficacy and influencing factors of irinotecan combined with the conventional chemotherapy regimen of oxaliplatin and fluorouracil in advanced gastric cancer patients. The results can provide valuable reference for clinical treatment and further study.

Research methods

Eighty patients with advanced gastric cancer were divided into two groups. The control group was given preoperative routine chemotherapy. The observation group was treated with irinotecan in addition to the chemotherapy given to the control group. The short-term efficacy of treatment in the two groups, as well as tumor marker levels and quality of life before and after treatment were evaluated.

Research results

The short-term treatment effect in the observation group was better than that in the control group. The median progression-free survival and overall survival were similar between two groups. The incidence rates of grade III-IV diarrhea and grade III-IV thrombocytopenia in the observation group were markedly higher than those in the control group. The age and proportion of tumor node metastasis (TNM) stage IV patients were notably higher, and the Karnofsky Performance Scale score was apparently lower in patients with ineffective chemotherapy.

Research conclusions

Chemotherapy combined with irinotecan in patients with advanced gastric cancer has a good short-term efficacy and can significantly reduce serum tumor markers and improve the quality of life of patients. The efficacy may be affected by the age and TNM stage of the patients.

Research perspectives

The long-term efficacy of chemotherapy combined with irinotecan need to be further studied.